WEBINAR ON-DEMAND

A Systematic Approach for Driving Cell Identity and Accelerating Regenerative Medicine

Mogrify icon (no text)

Explore how Mogrify®, using its proprietary suite of platform technologies that enable systematic identification of the key transcriptomic and epigenetic switches to drive the speed, efficiency and maintenance of cell conversions, offers a transformative approach to the development of ’off-the-shelf’ cell therapies, reducing the processing time of cell differentiation, and reducing variability between batches, whilst at the same time increasing the scalability of the cell products and facilitating an entirely new class of in vivo reprogramming therapies.

In this webinar, we will explore:

  • The challenges associated with the delivery of existing cell therapies;
  • How harnessing computational biology will drive the development of future cell and gene therapy products;
  • Applying MOGRIFY® in cell & gene therapy: opportunities to transform ex vivo cell therapy programs and pioneer a new class of in vivo reprogramming therapies.

Speakers:

Aida_Moreno_Moral

Dr. Aida Moreno-Moral
Principal Bioinformatician, Mogrify

Aida completed her PhD in Cardiovascular System Genetics at Imperial College London, UK. In her PhD she carried out high-throughput omics data integration across species to uncover novel targets for cardiovascular disease. This work led to a National Medical Research Council grant at Duke-NUS Medical School, Singapore, where Aida worked in the discovery and development of therapeutic targets for fibrotic, autoimmune diseases, and cell therapies.

Pierre-Louis-Joffrin

Pierre-Louis Joffrin
Corporate Development Executive, Mogrify

Pierre-Louis has a background in biochemistry and pharmacology from the University of St Andrews and the University of Oxford. He previously worked in early-stage venture development and investment at Oxford Sciences Innovations (OSI) and Deep Science Ventures (DSV) before joining Mogrify.

 
ABOUT US
Mogrify® will transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies.